RxDoctor Payments Data

Tanu Chandra, MD

Endocrinology, Diabetes & Metabolism · Monroe, NCNPI 1568626182

Payments from drug & device makers

$175in general payments, 2019–2025

Across 8 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$31
  • Insulet Corporation$28
  • Ascensia Diabetes Care US Inc.$26
  • Medtronic$22
  • Amgen$21
  • Corcept Therapeutics$21
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$175100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$175 in reported general payments places this provider in the 15th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina

Medicare billing

Part B allowed, 2024
$144,149
Medicare patients
255
Services billed
3,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide426$748,088
MounjaroTirzepatide155$243,412
JardianceEmpagliflozin124$140,459
Tresiba Flextouch U-100Insulin Degludec170$108,147
Tresiba Flextouch U-200Insulin Degludec56$63,304
RybelsusSemaglutide51$61,410
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog89$53,923
Humulin R U-500 KwikpenInsulin Regular, Human34$47,038
TrulicityDulaglutide37$43,476
Fiasp FlextouchInsulin Aspart (Niacinamide)39$42,653
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/755$37,796
Novolog FlexpenInsulin Aspart126$34,522
Humalog Kwikpen U-100Insulin Lispro122$33,950
Humalog Kwikpen U-200Insulin Lispro12$25,964
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$22,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$12$812,211489 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

Other endocrinology, diabetes & metabolism in Monroe

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →